Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX™

International Journal of Oncology

Volumn 12, Issue 6, 1998, Pages 1229-1235

  Hariharan, Kandasamy ^a   Braslawsky, Gary ^a   Barnett, Richard S ^a   Berquist, Lisa G ^a   Huynh, Tri ^a   Hanna, Nabil ^a   Black, Amelia ^a  

^a BIOGEN   (United States)

Author keywords

Adjuvant formulation; Cancer vaccines; Cytotoxic T lymphocyte vaccines; Human papillomavirus vaccines; PROVAX

Indexed keywords

IMMUNOLOGICAL ADJUVANT; PROVAX; RECOMBINANT VACCINE; RECOMBINANT VIRUS PROTEIN E7; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; LYMPHOCYTE DEPLETION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR REGRESSION; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION; IMMUNITY, CELLULAR; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINATION; VIRAL VACCINES;

EID: 0031842496     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.6.1229     Document Type: Article

References (44)

1. Lowy DR, Kimbauer R and Schiller JT: Genital human papilloma-virus infection. Proc Natl Acad Sci USA 91: 2346-2440, 1994.
2. Crawford L: Prospect of cervical cancer vaccines. Cancer Surv 16: 215-229, 1993.
3. Von Knebel Doeberitz M, Oltersdorf T, Schwarz E and Gissman L: Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 48: 3780-3786, 1988.
4. Vousden KH, Doniger J, Di Paolo JA and Lowy DR: The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res 2: 167-175, 1988.
5. Munger K, Phelps WC, Buvv V, Howley PM and Schlegel R: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 10: 4417-4421, 1989.
6. Seedorf K, Oltersdorf T, Krammer G and Rowekamp W: Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J 6: 139-144, 1987.
7. Laga M, Icenogle JP, Marsella R, Manoka AT, Nzila N, Ryder RW, Vermin SH, Heyward WL, Nelson A and Reeves WC: Genital papillomavirus infection and cervical dysplasia - opportunistic complications of HIV infection. Int J Cancer 50: 45-48, 1992.
8. Sheil AG: Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc 24: 1255-1259, 1992.
9. Wu T-C: Immunology of the human papilloma virus in relation to cancer. Curr Opin Immunol 6: 746-754, 1994.
10. Tindle RW and Frazer IH: Immunology of anogenital human papillomavirus (HPV) infection. Aust NZJ Obstet Gynecol 30: 370-375, 1990.
11. Melief CJ: Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 58: 143-175, 1992.
12. Greenberg PD: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49: 281-355, 1991.
13. Baxevanis CN and Papamichail M: Characterization of the antitumor immune response in human cancers and strategies for immunotherapy. Crit Rev Oncol Hematol 16: 157-179, 1994.
14. Ward PL and Schrieber H: Tumor antigens recognized by T cells. In: Biological Approaches to Cancer Treatment: Biomodulation. Mitchel MS (ed.) McGraw Hill, Inc., New York, pp72-97, 1993.
15. Matsumura M, Fremont DH, Peterson PA and Wilson IA: Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 257: 927-934, 1992.
16. Long EO: Intracellular traffic and antigen processing. Immunol Today 10: 232-234, 1989.
17. Townsend A, Ohlen C, Bastin J, Ljunggren H-G, Foster L and Kärre K: Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 340: 443-448, 1989.
18. Talarico D, Ittman M, Belsari A, Delli-Bori P, Basch RS and Basilico C: Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor. Proc Natl Acad Sci USA 87: 4222-4225, 1990.
19. Moore MW, Carbone FR and Bevan MJ: Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785, 1988.
20. Carbone FR and Bevan MJ: Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 171: 377-397, 1990.
21. Deres K, Schild H, Wiesmüller KH, Lang G and Rammensee HG: In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342: 561-564, 1989.
22. + cytotoxic T lymphocyte responses. J Immunol 14: 344-348, 1992.
23. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMS. Nature 344: 873-875, 1990.
24. Zhou F, Rouse BT and Huang L: Prolonged survival of thymoma entrapped in liposomes: a model study. Cancer Res 52: 6287-6291, 1992.
25. Raychaudhuri S, Tonks M, Carbone FR, Ryskamp T, Morrow WJW and Hanna N: Induction of antigen-specific class I-restricted cytotoxic cells by soluble proteins in vivo. Proc Natl Acad Sci USA 89: 8308-8312, 1992.
26. Hariharan K, Braslawsky G, Black A, Raychaudhuri S and Hanna N: The induction of cytotoxic T cells and tumor regression by soluble antigen formulation. Cancer Res 55: 3486-3489, 1995.
27. Fenton RG, Keller CJ, Hanna N and Taub DD: Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J Natl Cancer Inst 87: 1853-1861, 1995.
28. Seedorf K, Krammer G, Durst M, Suhai S and Rowekamp W: Human papillomavirus type 16 DNA sequence. Virology 145: 181-185, 1985.
29. Maniatis T, Fritsh EF and Sambrook J: Molecular Cloning, A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.
30. Guide for the Care and Use of Laboratory Animals. DHHS Publ. No. (NIH) 86-23, Bethesda, MD, NIH, 1985.
31. Winer BJ: Statistical Principles in Experimental Designs. McGraw-Hill Bank Co., New York, pp514-539, 1971.
32. Moss B: Vaccinia virus: a tool for research and vaccine development. Science 252: 1662-1667, 1991.
33. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL, De Lisi C, Moss B, Germain RN and Berzofsky JA: An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 85: 3105-3109, 1988.
34. Aldovini A and Young RA: Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351: 479-482, 1991.
35. Sadoff JC, Ballou WR, Baron LS, Majarian WR, Brey RN, Hockmeyer WT, Yound JF, Ou J, Lowell GH and Chulay JD: Oral salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240: 336-338, 1988.
36. Ulmer JB, Donnelly JJ, Parker SE, et al: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749, 1993.
37. + cytotoxic T-cell responses? A paradox revisited. Immunol Today 14: 344-348, 1993.
38. Souberbielle BE, Knight BC, Morrow WJW, Darling D, Fraziano JB, Cookson MS, Farzaneh F and Dalgleish AG: Comparison of IL2 and IL4 transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B 16-F10 whole cell tumor vaccine. Gene Ther 3: 853-858, 1996.
39. Meneguzzi G, Cerni C, Kieny MP and Lathe R: Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181: 62-69, 1991.
40. Chen LP, Thomas EK, Hu SL, Hellstrom I and Hellstrom KE: Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 88: 110-114, 1991.
41. Chen L, Ashe S, Brady WA Hellstrom, I Hellstrom KE, Ledbetter JA, McGowan P and Linsley PS: Co-stimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-1102, 1992.
42. Feltkamp M, Smits H, Vierboom M, et al: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242-2249, 1993.
43. Sadovnikova E and Stauss HJ: T Cell epitopes in human papilloma virus proteins. Behring Inst Mitt 94: 87-93, 1994.
44. d mice. Scand J Immunol 42: 557-563, 1995.